sre-37 Antibody

What is IL-37 and what role does it play in the immune system?

IL-37 is a member of the interleukin 1 cytokine family (also known as IL-1F7 and IL-1H4) that functions as a natural inhibitor of immune responses. It suppresses both innate inflammatory and immune responses, exhibiting anti-inflammatory characteristics similar to those of IL-1R8. IL-37 has been shown to down-regulate the expression of pro-inflammatory cytokines in chronic inflammatory diseases, suggesting it plays a crucial role in modulating inflammatory responses. Transcripts of IL-37 have been detected in various human tissues, including lung, testis, and colon tumors, as well as in some human cell lines .

What are the different isoforms of IL-37 and their distinguishing features?

IL-37 exists in five splice variants (IL-37a through IL-37e), with IL-37b being the longest and most extensively studied isoform. A key distinguishing feature is that only IL-37b and IL-37c express an N-terminal caspase-1 cleavage site. IL-37b shares significant sequence similarity with IL-18 and has been the primary focus of research due to its well-documented anti-inflammatory properties. The structural variations between these isoforms likely contribute to their differential expression patterns and potentially distinct biological functions in various tissues and disease states .

How does IL-37 interact with other immune system components?

IL-37 exhibits multiple interactions with other immune system components that explain its immunomodulatory effects. It binds to the alpha chain of IL-18R with low affinity but does not recruit the essential signaling co-receptor IL-18 beta or mediate pro-inflammatory activity. Additionally, IL-37 binds to IL-18 binding protein (IL-18BP) and enhances its antagonistic effects. Importantly, IL-37 forms a trimeric complex with IL-18BP and IL-18R beta, which results in the blockade of IL-18 activity. These interactions collectively contribute to IL-37's role in suppressing immune responses and reducing inflammation .

What methodologies are employed in developing high-specificity monoclonal antibodies against IL-37?

Development of high-specificity monoclonal antibodies against IL-37 typically follows a well-established hybridoma technology protocol. The process begins with immunizing BALB/c mice with prokaryotic expressed soluble human IL-37b recombinant protein. After confirming adequate antibody titers by indirect ELISA, splenocytes are isolated from immunized mice and fused with SP2/0 myeloma cells using polyethylene glycol (PEG). The resulting hybridomas are cultured in HAT medium and screened by indirect ELISA using prokaryotic expressed soluble human IL-37b protein. Selected hybridoma cell lines producing antibodies with high specificity and titer are further expanded for monoclonal antibody production. This methodology ensures the generation of antibodies that specifically recognize human IL-37b with high affinity .

What validation techniques ensure the specificity and functionality of IL-37 antibodies?

Multiple validation techniques are essential to confirm the specificity and functionality of IL-37 antibodies:

• Western blot analysis using IL-37-GFP fusion proteins expressed in 293-T cells to verify recognition of the target protein at the expected molecular weight

• Flow cytometry with cells transfected with IL-37-GFP to confirm antibody binding to intracellular IL-37

• Immunohistochemistry staining of tissues known to express IL-37

• Competitive binding assays to assess affinity

• Cross-reactivity testing against other IL-1 family members to ensure specificity

For instance, studies have shown that high-quality IL-37b monoclonal antibodies developed through hybridoma technology successfully recognize a 42 kDa band corresponding to IL-37-GFP fusion protein in Western blot analyses, confirming their specificity and utility for research applications .

How are IL-37 antibodies optimally labeled for various detection methods?

IL-37 antibodies can be labeled through several methods depending on the intended application. For flow cytometry, monoclonal antibodies are commonly conjugated with fluorochromes such as PE (phycoerythrin), which provides optimal excitation at 488-561 nm and emission at 578 nm. This enables detection using blue, green, or yellow-green lasers. The conjugation process must preserve antibody functionality while providing sufficient signal intensity. For example, the 37D12 monoclonal antibody has been successfully conjugated to PE for intracellular staining and flow cytometric analysis, with a recommended usage of 5 μL (0.06 μg) per test in a final volume of 100 μL, containing between 10^5 to 10^8 cells .

How are IL-37 antibodies utilized in studying inflammatory disease mechanisms?

IL-37 antibodies serve as essential tools for investigating inflammatory disease mechanisms through multiple approaches. They enable the visualization and quantification of IL-37 expression in various tissues and disease states, allowing researchers to correlate IL-37 levels with disease severity or progression. In flow cytometry, labeled IL-37 antibodies facilitate detection of intracellular IL-37 in specific cell populations, providing insights into which cells produce this anti-inflammatory cytokine during disease processes. Western blotting with IL-37 antibodies helps monitor changes in IL-37 expression under different inflammatory conditions. These applications collectively contribute to understanding IL-37's role in diseases like psoriasis, systemic lupus, and inflammatory bowel conditions where IL-37 has demonstrated regulatory functions .

What insights have IL-37 antibodies provided in cardiovascular research?

IL-37 antibodies have contributed significantly to understanding cardiovascular disease mechanisms, particularly in acute coronary syndrome. Research has revealed that immune complexes formed by antibodies against proteins like LL-37 (which shares some functional similarities with IL-37) can contribute to platelet activation and subsequent clot formation. Studies utilizing specific antibodies have demonstrated that in acute coronary syndrome, platelets remain persistently activated even after a heart attack, potentially due to immune complex formation. IL-37 antibodies have helped elucidate how the immune system's response to certain proteins might predispose individuals to cardiovascular events, suggesting potential targets for therapeutic intervention in heart disease .

How can IL-37 antibodies be employed to study cytokine interaction networks?

IL-37 antibodies facilitate detailed investigation of cytokine interaction networks through several methodological approaches:

• Co-immunoprecipitation studies using IL-37 antibodies can identify binding partners of IL-37

• Proximity ligation assays with IL-37 antibodies help visualize protein-protein interactions in situ

• Flow cytometry with multiple labeled antibodies, including IL-37 antibodies, enables analysis of cytokine expression patterns in individual cells

• IL-37 neutralizing antibodies can block IL-37 function to assess downstream effects on other cytokines

These approaches have revealed IL-37's interactions with IL-18R, IL-18BP, and IL-18R beta, forming a trimeric complex that blocks IL-18 activity. This understanding of IL-37's position within cytokine networks provides insights into how it modulates inflammatory responses and suggests potential intervention points for treating inflammatory conditions .

What protein delivery systems optimize IL-37 antibody efficacy in model organisms?

Advanced protein delivery systems can significantly enhance IL-37 antibody efficacy in model organisms like C. elegans. A particularly effective method involves encapsulating antibodies within cationic lipid vesicles prior to administration. This approach protects proteins from degradation in the digestive tract and promotes their absorption into body tissues. The technique involves preparing liposomes with specific lipid compositions that can effectively encapsulate antibodies while maintaining their functional integrity. When applied to antibody delivery in C. elegans models, this method has demonstrated successful outcomes, including phenotype rescue in disease models. Though not specifically tested with IL-37 antibodies, this approach has proven effective for other therapeutic antibodies, suggesting its potential utility for IL-37 research in model organisms .

How can researchers resolve contradictory findings in IL-37 expression studies?

Contradictory findings in IL-37 expression studies can be addressed through several methodological improvements:

• Employing multiple detection methods (qPCR, Western blot, flow cytometry) with validated IL-37 antibodies

• Using isotype controls and competitive binding assays to confirm antibody specificity

• Analyzing multiple IL-37 isoforms separately, as expression patterns may differ between IL-37a-e

• Standardizing experimental conditions, including cell activation states and tissue preparation protocols

• Implementing proper statistical analyses accounting for biological variability

Researchers should acknowledge that IL-37 expression varies significantly between tissues and disease states. The existence of five splice variants complicates interpretation, as different antibodies may preferentially detect specific isoforms. Rigorous validation of antibody specificity for the intended isoform and consistent methodology across experiments are essential for resolving apparent contradictions in expression data .

What are the technical considerations for studying IL-37 in clinical samples?

Studying IL-37 in clinical samples presents several technical challenges requiring specific considerations:

• Sample preparation must preserve IL-37 integrity, often requiring immediate processing or specialized preservation methods

• Intracellular staining protocols for flow cytometry must be optimized with appropriate permeabilization reagents (e.g., BD FACS permeabilizing solution)

• Antibody concentration requires careful titration for each application, with recommended starting points of 5 μL (0.06 μg) per test for flow cytometry

• Patient heterogeneity necessitates careful matching of cases and controls for factors like age, sex, and medication status

• Interpretation of results should account for IL-37's complex regulation and the presence of multiple isoforms

For flow cytometric analysis, researchers should follow validated protocols such as the two-step protocol for intracellular proteins, use appropriate isotype controls, and determine optimal cell numbers (typically ranging from 10^5 to 10^8 cells/test) empirically for each clinical sample type .

What are common challenges in IL-37 detection and how can they be overcome?

Several challenges frequently arise in IL-37 detection experiments, each requiring specific mitigation strategies:

• Low expression levels: Enhance detection sensitivity using signal amplification methods or concentrated samples

• Background signals: Implement stringent blocking steps and validate antibody specificity through competitive binding assays

• Cross-reactivity with other IL-1 family members: Select antibodies specifically validated against multiple IL-1 cytokines

• Isoform-specific detection issues: Choose antibodies targeting conserved regions (for pan-IL-37 detection) or unique epitopes (for isoform specificity)

• Protein degradation: Add protease inhibitors during sample preparation and maintain appropriate cold chain

For Western blotting applications, researchers should optimize primary antibody concentration through titration experiments, use appropriate membrane blocking agents, and consider enhanced chemiluminescence detection systems like FluorChemTM FC3 for improved sensitivity when working with low abundance IL-37 proteins .

How should researchers design controls for IL-37 antibody experiments?

Proper experimental controls are crucial for reliable IL-37 antibody research:

• Positive controls: Include samples with confirmed IL-37 expression (e.g., transfected 293-T cells expressing IL-37-GFP)

• Negative controls: Use untransfected cells or tissues known not to express IL-37

• Isotype controls: Include matched isotype IgG antibodies in flow cytometry to establish background staining levels

• Specificity controls: Perform pre-absorption tests with recombinant IL-37 protein

• Technical replicates: Include multiple measurements within the same experiment

• Biological replicates: Test independent biological samples to account for natural variability

In flow cytometry applications specifically, matched isotype IgG controls are essential for establishing gating strategies and determining positive staining thresholds. This approach helps distinguish specific IL-37 staining from background fluorescence, improving data reliability .

What approaches can optimize the sensitivity of IL-37 detection in low-expression contexts?

Enhancing IL-37 detection sensitivity in contexts with low expression requires specialized approaches:

• Signal amplification techniques: Use biotin-streptavidin systems or tyramide signal amplification

• Sample enrichment: Concentrate protein samples through immunoprecipitation prior to analysis

• Advanced detection platforms: Employ digital ELISA or other single-molecule detection methods

• Optimized antibody conjugation: Select brightest fluorophores (e.g., PE, APC) for flow cytometry

• Enhanced imaging techniques: Utilize confocal microscopy with signal enhancement for tissue analysis

For intracellular flow cytometry applications, researchers should optimize permeabilization conditions to maximize antibody access to intracellular epitopes while preserving cell integrity. The Intracellular Fixation & Permeabilization Buffer Set has been validated for IL-37 detection in human peripheral blood cells when used with appropriate monoclonal antibodies at optimized concentrations .